



The Future of Cord Blood Derived Cell Therapies

Saturday, November 11, 2017

10:00 a.m. – 11:00 a.m.

Speaker

John E. Wagner MD

Session Objectives

At the conclusion of this session, attendees will be able to:

1. List the advantages and disadvantages of cord blood hematopoietic cell transplantation.
2. Describe the role of CD34 expansion in cord blood transplantation.
3. State the future of umbilical cord blood - derived cell therapies.

Conflict of Interest/Financial Disclosure

The planners and speaker(s) have disclosed the following financial relationships and/or conflicts of interest:

Del Steckler, RN, BSN, MMA	None
John E. Wagner, MD	Novartis – Contract
Merry Duffy	None